Adverse events in children and adolescents treated with quetiapine

Jakobsen, Klaus D.; Kildemoes, Helle Wallach; Bruhn, Christina Hedegaard; Hashemi, Nasseh; Pagsberg, Anne Katrine; Fink-Jensen, Anders; Nielsen, Jimmi

doi:10.1097/yic.0000000000000148

Cited by 9 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, extremely limited guidelines for its use are available in this population. A recent nationwide report demonstrated that off-label use of quetiapine in children and adolescents is prevalent in Denmark, and life-threatening adverse events involved seizure, QT-interval prolongation, and cerebral hemorrhage 3. Besides, this study implied that quetiapine could induce hyperprolactinemia, especially in minors 3.…”

Section: Introductionmentioning

confidence: 63%

“…A recent nationwide report demonstrated that off-label use of quetiapine in children and adolescents is prevalent in Denmark, and life-threatening adverse events involved seizure, QT-interval prolongation, and cerebral hemorrhage 3. Besides, this study implied that quetiapine could induce hyperprolactinemia, especially in minors 3. Moreover, in some susceptible individuals, exposure to quetiapine overdoses can result in severe complications, such as coma, seizure, respiratory depression, arrhythmia, and even death 4.…”

Section: Introductionmentioning

confidence: 73%

See 1 more Smart Citation

Convulsive syncope related to a small dose of quetiapine in an adolescent with bipolar disorder

Lai

Huang

et al. 2017

NDT

View full text Add to dashboard Cite

Quetiapine, an atypical antipsychotic, has been extensively used in patients with bipolar disorder. Overdose of quetiapine can result in severe complications, such as coma, seizure, respiratory depression, arrhythmia, and even death. However, the paucity of toxicological evaluation in adolescence causes more potential risks in this population. Herein, we present a case of hypotension and convulsive syncope after exposure to a small dose of quetiapine in a 16-year-old who was diagnosed with bipolar disorder. After cessation of quetiapine, no additional convulsive movements were reported. This case indicates that even in young patients without predisposing factors, close monitoring of adverse effects should be warranted for safety concerns, especially at the initiation of quetiapine treatment.

show abstract

Section: Introductionmentioning

confidence: 63%

Section: Introductionmentioning

confidence: 73%

Convulsive syncope related to a small dose of quetiapine in an adolescent with bipolar disorder

Lai

Huang

et al. 2017

NDT

View full text Add to dashboard Cite

show abstract

“…192 Since some of those adverse events are life threatening, the off-label use of quetiapine in children and adolescents gives rise to safety concerns. 236 antagonist at dopamine D2 and D3 receptors. The body of evidence on the effectiveness of tiapride in the treatment of tics is still small.…”

Section: Systematic Review Of Dopamine Receptormentioning

confidence: 99%

Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents

Mogwitz

Buse

Wolff

et al. 2018

ACS Chem. Neurosci.

View full text Add to dashboard Cite

More than 40 years of research and clinical practice have proven the effectiveness of dopamine receptor antagonists in the pharmacological treatment of tics. A blockade of the striatal dopamine-D2 receptors is mainly responsible for their tic-reducing effect. A broad spectrum of dopamine-modulating agents, such as typical and atypical antipsychotics, but also dopamine receptor agonists are used with an immanent discord between experts about which of them should be considered as first choice. The present Review outlines the state of the art on pharmacological treatment of tics with dopamine-modulating agents by giving an systematic overview of studies on their effectiveness and a critical discussion of their specific adverse effects. It is considered as an update of a previous review of our research group published in 2013. The Review closes with a description of the current resulting treatment recommendations including the results of a first published revised survey on European expert's prescription preferences. Based on the enormously growing evidence on its effectiveness and safety, aripiprazole currently seems to be the most promising agent in the pharmacological treatment of tics. Furthermore, benzamides (especially tiapride), which are commonly used in Europe, have proven their excellent effectiveness-tolerability profile over decades in clinical practice and are therefore also highly recommended for the treatment of tics. Nevertheless, pharmacological treatment of tics remains an indiviual choice depending on each patient's own specific needs.

show abstract

“…Both researches by Wenzel‐Seifert et al 9 and Hasnain et al 10 observed that torsade de pointes (TdP) was in association with the use of newer antipsychotic drugs, which mainly included quetiapine. The widely reported cardiovascular side effects have also raised concerns of the Danish Medicine Agency or the European Medicine Agency, which has therefore been cautious about expanding the use of quetiapine 11,12 . In particular, the FDA have warned in the instructions that elderly patients with dementia‐related psychosis was associated with an increased risk of death from cardiovascular diseases (e.g., heart failure, sudden death) and infections (e.g., pneumonia) when treated with quetiapine.…”

Section: Introductionmentioning

confidence: 99%

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system

et al. 2023

View full text Add to dashboard Cite

Objective Quetiapine, an atypical second‐generation antipsychotic drug, is approved for treatment of schizophrenia, bipolar disorder, and depression. Due to the limitations of clinical trials, the association between quetiapine and rare cardiac adverse events (AEs) is still unclear. This study is to evaluate quetiapine‐associated cardiac AEs through data mining of FDA Adverse Event Reporting System (FAERS). Methods Reporting odds ratio (ROR) was used to quantify the signals of quetiapine‐related cardiac AEs from the first quarter (Q1) of 2018–2022 Q1. Serious and nonserious cases were compared, and signals were prioritized using a rating scale. Results A total of 1004 cases of quetiapine‐associated cardiac AEs were identified, with 31 signals being detected, among which 13 AEs were identified as new and unexpected signals. Besides, nine and 22 cardiac AEs were identified as moderate and weak clinical priority. The median TTO for moderate and weak clinical priority signals were 0 and 4 days, respectively. All of the cardiac AEs had early failure type characteristics, suggesting that most of the patients developed cardiac AEs in a few days after quetiapine treatment, and that the risk of cardiac AEs occurrence would be gradually decreased over time. Conclusion Our study provided valuable evidence for health‐care professionals to mitigate the risk of quetiapine‐associated cardiac AEs based on an extensive analysis of a real‐world, large‐sample FAERS database, and prioritize cardiac AE signals.

show abstract

Adverse events in children and adolescents treated with quetiapine

Cited by 9 publications

References 15 publications

Convulsive syncope related to a small dose of quetiapine in an adolescent with bipolar disorder

Convulsive syncope related to a small dose of quetiapine in an adolescent with bipolar disorder

Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system

Contact Info

Product

Resources

About